Literature DB >> 2560771

Resolution of small cell lung cancer intracranial metastases with standard dose chemotherapy.

F Kearns, L Grogan, P Harford, D N Carney.   

Abstract

Brain metastases are a well recognized problem in patients with small cell lung cancer (SCLC). Most patients are treated with whole brain cranial irradiation therapy which frequently improves symptoms. In this report we present data on two patients who achieved radiologically confirmed complete resolution of brain metastases treated with standard dose chemotherapy for SCLC.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2560771     DOI： 10.1007/BF02983695

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN： 0021-1265            Impact factor:   1.568


  5 in total

1.  CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival.

Authors:  J L Nugent; P A Bunn; M J Matthews; D C Ihde; M H Cohen; A Gazdar; J D Minna
Journal:  Cancer       Date:  1979-11       Impact factor: 6.860

Review 2.  Prophylactic cranial irradiation and small cell lung cancer.

Authors:  A G Pedersen; P E Kristjansen; H H Hansen
Journal:  Cancer Treat Rev       Date:  1988-06       Impact factor: 12.111

3.  Successful management of metastatic and primary germ cell tumors in the brain.

Authors:  G J Rustin; E S Newlands; K D Bagshawe; R H Begent; S M Crawford
Journal:  Cancer       Date:  1986-06-01       Impact factor: 6.860

4.  Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.

Authors:  P E Postmus; J J Holthuis; H Haaxma-Reiche; N H Mulder; L M Vencken; W J van Oort; D T Sleijfer; H J Sluiter
Journal:  J Clin Oncol       Date:  1984-03       Impact factor: 44.544

5.  High dose etoposide for brain metastases of small cell lung cancer. A phase II study. The EORTC Lung Cancer Cooperative Group.

Authors:  P E Postmus; H Haaxma-Reiche; D T Sleijfer; A Kirkpatrick; J G McVie; J P Kleisbauer
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.